Holen Sie sich die Stockscreener-App
12.59
2.14%
-0.29
Handel nachbörslich:
12.85
0.26
+2.07%
Schlusskurs vom Vortag:
$12.88
Offen:
$12.85
24-Stunden-Volumen:
1.24M
Relative Volume:
0.73
Marktkapitalisierung:
$3.96B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-18.50
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
-2.06%
1M Leistung:
+0.68%
6M Leistung:
+55.81%
1J Leistung:
+59.15%
1-Tages-Spanne:
$12.59
$12.91
1-Wochen-Bereich:
$12.61
$13.01
52-Wochen-Spanne:
$6.685
$13.01
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.59 | 4.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
125.80 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.12 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharma-mAbxience gets USFDA approval for Boncresa, Oziltus - Medical Dialogues
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Short Squeeze: Why Amneal Pharmaceuticals Inc stock remains a top recommendation2025 Key Highlights & Community Verified Watchlist Alerts - moha.gov.vn
FDA approves Amneal’s two denosumab biosimilars for US market By Investing.com - Investing.com Nigeria
Amneal stock rises after FDA approves two denosumab biosimilars By Investing.com - Investing.com Australia
Amneal Reports FDA Approval of Denosumab Biosimilars - marketscreener.com
Amneal stock rises after FDA approves two denosumab biosimilars - Investing.com
FDA approves Amneal’s two denosumab biosimilars for US market - Investing.com
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - The Manila Times
FDA OKs new biosimilar bone drugs for cancer and osteoporosis - Stock Titan
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection - Sahm
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Market Leaders: What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Momentum & High Return Stock Watch Alerts - Улправда
What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
Operating cash flow per share of Amneal Pharmaceuticals, Inc. Class A – DUS:2DT - TradingView — Track All Markets
New Highs: Is Amneal Pharmaceuticals Inc. stock overvalued by current metrics2025 Risk Factors & High Accuracy Swing Trade Signals - Улправда
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsJuly 2025 Selloffs & Accurate Intraday Trading Signals - DonanımHaber
Will Amneal Pharmaceuticals Inc. stock recover faster than peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - DonanımHaber
Can Amneal Pharmaceuticals Inc. stock continue upward trendProduct Launch & Low Risk Entry Point Tips - DonanımHaber
Aug Patterns: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com South Africa
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockMarket Volume Report & Daily Risk Controlled Trade Plans - Улправда
Why Amneal Pharmaceuticals Inc. stock attracts global investorsMarket Risk Analysis & Real-Time Price Movement Reports - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Decliners & Free High Accuracy Swing Entry Alerts - Улправда
Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
Yakima Topic AMNEAL PHARMACEUTICALS, INC. | News, Weather, Sports, Breaking News - KIMA
Squarepoint Ops LLC Buys 420,398 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Institutional Investors Have a Lot Riding on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) With 48% Ownership - 富途牛牛
Esomeprazole Market Set to Witness Significant Growth - openPR.com
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Increased by BlackBarn Capital Partners LP - MarketBeat
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated at Barclays - MarketBeat
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care - Investing.com
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewswire
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.30%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):